Literature DB >> 30554845

Impact of short-incubation MALDI-TOF MS on empiric antibiotic therapy in bloodstream infections caused by Pseudomonas aeruginosa, Enterococcus spp. and AmpC-producing Enterobacteriaceae.

Mika Halavaara1, Annika Nevalainen2, Timi Martelius3, Pentti Kuusela2, Veli-Jukka Anttila3.   

Abstract

The impact of the short-incubation matrix-assisted laser desorption ionization time-of-flight (si-MALDI-TOF) mass spectrometry technique was evaluated in the treatment of bloodstream infections (BSIs) caused by Pseudomonas aeruginosa, Enterococcus spp., and Amp-C producing Enterobacteriaceae. A total of 124 bacteremia episodes were divided into 2 groups: i) si-MALDI-TOF group (n = 69) and ii) control group (n = 55). Identification by si-MALDI-TOF resulted in 12.8% increase in cases receiving appropriate antibiotic treatment within 48 h from blood culture draw. The importance of the rapid identification was emphasized in BSIs caused by enterococci (n = 62), where si-MALDI-TOF led to appropriate antibiotic treatment in 87.9% of cases (versus control group 65.5%, P = 0.036). Implementation of si-MALDI-TOF technology for microbial identification was associated with increased proportion of patients receiving effective antibiotic treatment within 48 h from blood culture draw. The effect was most significant in BSIs caused by enterococcal species and in a subgroup of immunosuppressed patients.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacteremia; Bloodstream infection; Empiric antibiotic treatment; MALDI-TOF; Short incubation

Mesh:

Substances:

Year:  2018        PMID: 30554845     DOI: 10.1016/j.diagmicrobio.2018.11.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  1 in total

1.  Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for positive blood cultures in clinical practice using a total lab automation.

Authors:  Jasmin Kaur Jasuja; Stefan Zimmermann; Irene Burckhardt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-02-28       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.